Risperidone Treatment of Autistic Disorder: Longer-Term Benefits and Blinded Discontinuation After 6 Months
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Risperidone is effective for short-term treatment of aggression, temper outbursts, and self-injurious behavior in children with autism. Because these behaviors may be chronic, there is a need to establish the efficacy and safety of longer-term treatment with this agent. METHOD: The authors conducted a multisite, two-part study of risperidone in children ages 5 to 17 years with autism accompanied by severe tantrums, aggression, and/or self-injurious behavior who showed a positive response in an earlier 8-week trial. Part I consisted of 4-month open-label treatment with risperidone, starting at the established optimal dose; part II was an 8-week randomized, double-blind, placebo-substitution study of risperidone withdrawal. Primary outcome measures were the Aberrant Behavior Checklist irritability subscale and the Clinical Global Impression improvement scale. RESULTS: Part I included 63 children. The mean risperidone dose was 1.96 mg/day at entry and remained stable over 16 weeks of open treatment. The change on the Aberrant Behavior Checklist irritability subscale was small and clinically insignificant. Reasons for discontinuation of part I included loss of efficacy (N=5) and adverse effects (N=1). The subjects gained an average of 5.1 kg. Part II included 32 patients. The relapse rates were 62.5% for gradual placebo substitution and 12.5% for continued risperidone; this difference was statistically significant. CONCLUSIONS: Risperidone showed persistent efficacy and good tolerability for intermediate-length treatment of children with autism characterized by tantrums, aggression, and/or self-injurious behavior. Discontinuation after 6 months was associated with a rapid return of disruptive and aggressive behavior in most subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lord, C., Rutter, M., & Le Couteur, A. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172145 · Cited by 9,065 · cited 1×
“At screening for participation in the initial 8-week treatment study, autistic disorder was ascertained through a history and examination by a research team and was corroborated by the Autism Diagnostic Interview—Revised (10), administered by a clinician trained to reliability (11).”
MethodA RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Pervasive Developmental Disorders in preschool children
Chakrabarti, S. (2001) · JAMA · doi:10.1001/jama.285.24.3093 · Cited by 1,132 · cited 1×
“Autistic disorder is characterized by impaired social interaction, abnormal language development, and repetitive and restricted patterns of behavior (DSM-IV), and it affects as many as 20 people per 10,000 (1, 2).”
BackgroundGibbons, R. D. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210073009 · Cited by 719
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.633 · Cited by 427
Diagnosing Autism: Analyses of Data from the Autism Diagnostic Interview
Lord, C., Pickles, A., McLennan, J., Rutter, M., Bregman, J., Folstein, S., Fombonne, E., Leboyer, M., & Minshew, N. (1997) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025873925661 · Cited by 373
The Vineland Adaptive Behavior Scales: Supplementary Norms for Individuals with Autism
Carter, A. S., Volkmar, F. R., Sparrow, S. S., Wang, J.-J., Lord, C., Dawson, G., Fombonne, E., Loveland, K., Mesibov, G., & Schopler, E. (1998) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1026056518470 · Cited by 367
Genetics and Child Psychiatry: II Empirical Research Findings
Rutter, M., Silberg, J., O'Connor, T., & Simonoff, E. (1999) · Journal of Child Psychology and Psychiatry · doi:10.1017/s0021963098003291 · Cited by 313
Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY). Part II
PAPPADOPULOS, E., MACINTYRE, J. C., CRISMON, M. L., FINDLING, R. L., MALONE, R. P., DERIVAN, A., SCHOOLER, N., SIKICH, L., GREENHILL, L., SCHUR, S. B., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200302000-00008 · Cited by 289
Research works printed but not linked: 1
- Findling RL, Maxwell K, Wiznitzer M: An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997; 33:155–159
Cited by
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
Management of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
Leekam, S. R., Prior, M. R., & Uljarevic, M. (2011) · Psychological Bulletin · doi:10.1037/a0023341 · Cited by 612
Aman, M. G., Mcdougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., Stigler, K. A., Bearss, K., Butter, E., Swiezy, N. B., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181bfd669 · Cited by 371
A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J. (2011) · Pediatrics · doi:10.1542/peds.2011-0427 · Cited by 356
Fung, L. K., Mahajan, R., Nozzolillo, A., Bernal, P., Krasner, A., Jo, B., Coury, D., Whitaker, A., Veenstra-Vanderweele, J., & Hardan, A. Y. (2016) · Pediatrics · doi:10.1542/peds.2015-2851k · Cited by 294
Validity of the Aberrant Behavior Checklist in Children with Autism Spectrum Disorder
Kaat, A. J., Lecavalier, L., & Aman, M. G. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1970-0 · Cited by 271
Aggression in autism spectrum disorder: presentation and treatment options
Fitzpatrick, S., Srivorakiat, L., Wink, L., Pedapati, E., & Erickson, C. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84585 · Cited by 271
Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes
CORRELL, C. U. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815b5cb1 · Cited by 254
Gastrointestinal symptoms in a sample of children with pervasive developmental disorders
Nikolov, R. N., Bearss, K. E., Lettinga, J., Erickson, C., Rodowski, M., Aman, M. G., McCracken, J. T., McDougle, C. J., Tierney, E., Vitiello, B., et al. (2009) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-008-0637-8 · Cited by 240
An update on pharmacotherapy for autism spectrum disorder in children and adolescents
Ji, N. Y., & Findling, R. L. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000132 · Cited by 217
Use of psychotropic medication in children and adolescents with autism spectrum disorders
Coury, D. L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., McCoy, R., Whitaker, A., & Perrin, J. M. (2012) · PEDIATRICS · doi:10.1542/peds.2012-0900d · Cited by 191
Sung, M., Ooi, Y. P., Goh, T. J., Pathy, P., Fung, D. S. S., Ang, R. P., Chua, A., & Lam, C. M. (2011) · Child Psychiatry & Human Development · doi:10.1007/s10578-011-0238-1 · Cited by 131
Anagnostou, E., Aman, M. G., Handen, B. L., Sanders, K. B., Shui, A., Hollway, J. A., Brian, J., Arnold, L. E., Capano, L., Hellings, J. A., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.1232 · Cited by 123
Disruptive Mood Dysregulation Disorder: A New Diagnostic Approach to Chronic Irritability in Youth
Roy, A. K., Lopes, V., & Klein, R. G. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101301 · Cited by 117
Matheson, B. E., & Douglas, J. M. (2017) · Review Journal of Autism and Developmental Disorders · doi:10.1007/s40489-017-0103-7 · Cited by 81
Psychopharmacology in autism: an update
Canitano, R., & Scandurra, V. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.10.015 · Cited by 79
Canitano, R. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1450 · Cited by 74
Unwin, G. L., & Deb, S. (2011) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2011.07.031 · Cited by 62
On Behalf of the ISACA Guideline Working Group, D’Alò, G. L., De Crescenzo, F., Amato, L., Cruciani, F., Davoli, M., Fulceri, F., Minozzi, S., Mitrova, Z., Morgano, G. P., et al. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01669-0 · Cited by 54
Récalt, A. M., & Cohen, D. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496734 · Cited by 38
Groves, L., Jones, C., Welham, A., Hamilton, A., Liew, A., & Richards, C. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00197-9 · Cited by 20
“9,13,19,20 Several initiatives have been published encouraging clinicians to review and, where appropriate, discontinue medication use for BtC (eg, stopping overmedication of people with a learning disability, autism, or both [STOMP]).”
BackgroundThe Clinician’s Guide to Autism
Harrington, J. W., & Allen, K. (2014) · Pediatrics In Review · doi:10.1542/pir.35.2.62 · Cited by 16
Metadata
- Authors
- Research Units on Pediatric Psychopharmacology Autism Network
- Venue
- American Journal of Psychiatry
- Published
- 2005-07-01
- Volume
- 162
- Issue
- 7
- Pages
- 1361-1369
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W106578406
- Cited by
- 288
- References
- 25
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.